DOSSIER · UPDATED 18 NOV 2025

Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.

rgentatx.com ↗Claim this profile
Founded
2018
Headcount
41
Open roles
0
Last raised
Series A · $8M
SECTION I · THE BRIEF

Inside Rgenta Therapeutics

Brief #71721Updated 18 NOV 2025BROOKLINEMEDICAL ORGANIZATIONSSERIES A
Employbl Dossier

Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.

Founded
2018
Headcount
41
Open roles
0
Last raised
Series A · $8M
Section II — RestrictedMembers only
  • Tech stack (Rgenta Therapeutics engineering primaries)
  • Hiring focus this quarter
  • Interview format & rubric
  • Comp bands by level
  • Decision-makers in talent
  • Recent news & moves
Open Rgenta Therapeutics briefSign in

7-day free trial · $25/mo · cancel anytime

TAGS

Categorized in

Company Collections

These are collections Rgenta Therapeutics is a part of. Click on the collection name to view similar companies.

Rgenta Therapeutics' Industries

LOCATIONS

Where they work

Rgenta Therapeutics Headquarters Location

15 Lincoln Road, Brookline, MA, 02445-6804

Loading map…
FUNDING

Capital raised

Total Amount Raised: $116,949,200

Rgenta Therapeutics Funding Rounds

  • Series A

    $8,000,000

  • Series A

    $8,000,000

    Series A Investors

    HighLight Capital
    The Leukemia & Lymphoma Society's Therapy Acceleration Program

  • Series A

    $52,000,000

  • Series A

    $52,000,000

    Series A Investors

    AstraZeneca
    CICC
    Delos Capital
    Korea Investment Partners
    Matrix Partners China
    Vivo Capital
    Lilly Asia Ventures
    Kaitai Capital
    Boehringer Ingelheim Venture Fund
    Legend Star

  • Series Unknown

    $8,914,283

  • Series Unknown

    $8,914,283

  • Seed

    $18,000,000

  • Seed

    $18,000,000

    Seed Investors

    Vivo Capital
    Lilly Asia Ventures
    Kaitai Capital

  • Seed

    $20,000,000

  • Seed

    $20,000,000

    Seed Investors

    Boehringer Ingelheim Venture Fund
    Matrix Partners China
    Kaitai Capital
    Legend Star

  • Series Unknown

    $10,034,915

  • Series Unknown

    $10,034,915

Funding info provided by Diffbot.
EMPLOYEE REVIEWS

On the ground at Rgenta Therapeutics

Rgenta Therapeutics Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Rgenta Therapeutics.

Recent reviews